Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @
Novartis Calls Avidity ‘Bump’ Normal, Sticks To Bolt-On M&A Strategy
NNovartis

Novartis Calls Avidity ‘Bump’ Normal, Sticks To Bolt-On M&A Strategy

  • 2026-11-03

Scrip logo

Novartis CEO Vas Narasimhan backs the company’s current M&A strategy, which is mainly focused on bolt-on deals under $2bn.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland. • Source: Archive

Novartis booked a $1.9bn partial impairment on del-desiran after the drug’s Phase III failure, but CEO Vas Narasimhan said the hit to its $12bn Avidity Biosciences acquisition does not change a strategy built on bolt-on deals under $2bn.

Key TakeawaysNovartis took a $1.9bn partial impairment on del-desiran after its Phase III failure, and a further pivotal study in myotonic dystrophy type 1 will delay any launch.

Speaking to reporters after third-quarter results, Narasimhan said the combined effect of the del-desiran and…

  • Tags:
  • Avidity
  • del-desiran
  • Narasimhan's outlook
  • Novartis
  • Novartis Q3 earnings
  • Rhapsido urticaria treatment
Switzerland
www.europesays.com